Saturday 17 October 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.
9.55
0.71
−6.92%
Follow MLTX
MoonLake Immunotherapeutics (MLTX) P/E ratio
MoonLake Immunotherapeutics has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 155× (December 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 155×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)